Pharming Group (NASDAQ:PHGUF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday. The firm currently has a $0.25 price target on the stock.
According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “
Shares of Pharming Group (NASDAQ:PHGUF) opened at 0.25 on Wednesday. The firm’s market capitalization is $103.15 million. The firm has a 50-day moving average price of $0.00 and a 200 day moving average price of $0.00. Pharming Group has a 12 month low of $0.17 and a 12 month high of $0.35.
Pharming Group Company Profile
Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.